Amrad posts end-of-year profit
26 August, 2003 by Melissa TrudingerIn a dramatic turnaround from last year's $14.4 million loss, Amrad (ASX:AML) has posted an inaugural after-tax profit of AUD$7.4 million for the 2002-2003 financial year, which includes $1.2 million operating profit in addition to the one-off profit realised from the sale of Amrad's Richmond property.
Metabolic brings in $12m through options
25 August, 2003 by Melissa TrudingerMetabolic Pharmaceuticals (ASX:MBP) is today heralding a recently finalised exercise of listed options had brought the company AUD$12 million.
EpiTan raises $7.4m in share placement
25 August, 2003 by Melissa TrudingerEpiTan (ASX:EPT) has raised nearly AUD$7.4 million in a share placement of 14.5 million shares priced at $0.51, providing cash reserves to see the company through to the end of 2004.
IDT posts record revenues
25 August, 2003 by Melissa TrudingerMelbourne-based drug development and manufacturing company Institute of Drug Technology Australia (ASX:IDT) has posted record revenues of AUD$25.8 million for the 2002-2003 financial year.
Benitec not likely to leave IMB: McKinley
22 August, 2003 by Jeremy TorrGene silencing specialist Benitec has denied rumours that it is to relocate from its IMB (Institute for Molecular Bioscience) base in Queensland to the US, claiming that North American media misreported the situation.
Antisense raises $5 million
22 August, 2003 by Jeremy TorrDrug discovery biotech Antisense Therapeutics (ASX:ANP) has added AUD$5 million to its coffers with the placement of 38.5 million new shares to the institutional and specialist investor market.
Norwood Abbey moves into Asia
22 August, 2003 by Jeremy TorrAs part of its strategy to move into the Asian region, Norwood Abbey has appointed a new commercial partner to market its range of laser assisted drug delivery products.
Vintage research benefits wine industry
21 August, 2003 by Graeme O'NeillOn a wall at CSIRO Plant Industry's Merbein laboratories, is an old photo-micrograph of a grapevine floral bud. Dr Nigel Steele Scott, head of Plant Industry's horticultural research laboratories in Glen Osmond, South Australia, says it's his favourite image -- a portent of a revolution in viticulture that is still having an enormous impact on the Australian wine industry today.
Peptech MD Kwik to resign
21 August, 2003 by Jeremy TorrPeptech is to lose its managing director Stephen Kwik in the first glimpse of what chairman Mel Bridges has dubbed a "broadening and deepening of scope" for the therapeutic peptide and protein biotech.
pSiMedica's BioSilicon to undergo tissue engineering trial
20 August, 2003 by Graeme O'NeillpSiMedica, a subsidiary of Perth-based pSivida (ASX: PSD), has signed an agreement with the UK-based McComb Foundation to evaluate its nanostructured porous silica material BioSilicon as a tissue-engineering substrate.
EpiTan answers ASX trading query
18 August, 2003 by Iain ScottMelbourne-based EpiTan's share price (ASX:EPT) has doubled since April, but that's just because of increased market awareness, the company has told the Australian Stock Exchange.
New fund aims to raise $150m for Australian biotech
18 August, 2003 by Iain ScottA new fund, spearheaded by stockbrokers Intersuisse, British VC Rothschild Bioscience Managers and Sequence Capital Group, aims to raise AUD$150 million and overseas backing for Australian biotech companies.
UK researcher's eyes opened by biotech activity down under
15 August, 2003 by Melissa TrudingerUK scientist and entrepreneur Prof Peter Shepherd is amazed at how much biotechnology activity there is in Australia.
AVI seeks orphan status for experimental SARS drug
15 August, 2003 by Staff WritersUS firm Avi BioPharma has asked US regulators to grant 'orphan' status to its experimental drug against the virus that causes SARS, a designation meant to provide seven years of marketing exclusivity for medicines.
Bionomics beefs financial team
15 August, 2003 by Jeremy TorrAdelaide-based genomics biotech Bionomics has appointed a new heavy hitter to its financial team with the signing up of ex-Faulding and ex-Mayne commercialisation expert Lee Craker as new CFO.
